Prothrombin complex concentrate (Cofact ®) as a potential antidote for novel anticoagulants Dabigatran and Rivaroxaban.
Recruiting
- Conditions
- Anticoagulants.Antidote for bleeding.
- Registration Number
- NL-OMON22423
- Lead Sponsor
- Prof. dr. M.M. Levi, Academic Medical Centre of Amsterdam
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 12
Inclusion Criteria
1. Healthy males between 18-50 year;
2. No medical history of thrombotic disease or bleeding disorders;
Exclusion Criteria
1. History of allergic reaction to blood products;
2. Current participation in any other investigational drug study or within the past 30 days.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome is activation and inhibition of coagulation, as reflected by coagulation tests.
- Secondary Outcome Measures
Name Time Method